When.com Web Search

  1. Ads

    related to: new drug for migraine
    • FAQs

      Find Answers to Frequently

      Asked Questions by Patients.

    • Doctor Discussion Guide

      Discussion Guide to Help Facilitate

      a Conversation with Your Doctor

Search results

  1. Results From The WOW.Com Content Network
  2. Meloxicam/rizatriptan - Wikipedia

    en.wikipedia.org/wiki/Meloxicam/rizatriptan

    Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. [1] It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist . [1] It is taken by mouth. [1]

  3. Academics said their findings are ‘important’ considering the higher costs of new treatments. Skip to main content. Subscriptions; Animals. Business. Entertainment. Fitness ...

  4. This New Nasal Spray Could Provide Migraine Relief in ... - AOL

    www.aol.com/nasal-spray-could-migraine-relief...

    Zavzpret is a new nasal spray to treat migraine headaches in adults. But how does the medication work and who should try the new FDA-approved medication?

  5. Eptinezumab - Wikipedia

    en.wikipedia.org/wiki/Eptinezumab

    The US Food and Drug Administration (FDA) approved eptinezumab based primarily on evidence from two clinical trials (Trial 1/NCT02559895 and Trial 2/NCT02974153) of 1741 participants with chronic or episodic migraine headaches. [10] Trials were conducted at 212 sites in United States, Georgia, Russia, Ukraine and the European Union. [10]

  6. A drug used in the prevention of migraine may also help reduce so-called rebound headaches, according to a new review of data from a randomized, double-blind, placebo-controlled migraine trial ...

  7. Galcanezumab - Wikipedia

    en.wikipedia.org/wiki/Galcanezumab

    The US Food and Drug Administration (FDA) approved galcanezumab based on evidence from three clinical trials (Trial 1/NCT02614183, Trial 2/NCT02614196, and Trial 3/NCT02614261) in 2156 adults 18 to 65 years of age with chronic or episodic migraine headaches. [10]

  1. Ad

    related to: new drug for migraine